Table 8.

Tremelimumab.

NCT Number	Status	Co-Treatment/Intervention	Phase	Participants	Results/Conclusions	References
NCT02527434	Active, not recruiting	Monotherapy Combination therapy with MEDI4736	II	12	1 patient completed, 11 not completed (death 6, withdrawal by subject 3, lost to follow-up 2)	[215]
NCT03982173	Active, not recruiting	Durvalumab	II	88	Estimated Study Completion Date April 2023	[216]
NCT02489448	Active, not recruiting	Nab-Paclitaxel, Durvalumab (MEDI4736)	I, II	71	Estimated Study Completion Date December 2021	[214]
NCT03606967	Recruiting	Carboplatin Durvalumab Gemcitabine Hydrochloride Nab-paclitaxel Personalized Synthetic Long Peptide Vaccine Poly ICLC	II	70	No Study Results Posted	[222]
NCT02658214	Completed	Platinum Durvalumab	I	32	No Study Results Posted	[230]
NCT03674827	Completed	A vaccine-based immunotherapy regimen (VBIR-2) (PF-06936308), Sasanlimab	I	36	No Study Results Posted	[239]